Taste Acceptability of Tomato-Soy-Arugula Seed Beverages in Men With Prostate Cancer
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02927899|
Recruitment Status : Active, not recruiting
First Posted : October 7, 2016
Last Update Posted : May 24, 2018
|Condition or disease||Intervention/treatment||Phase|
|Prostate Carcinoma||Other: Survey Administration Dietary Supplement: Tomato-Soy Juice||Not Applicable|
I. To evaluate the sensory acceptability of a novel tomato-soy-arugula seed beverage in men with prostate cancer.
Patients receive 4 tomato-soy beverages and 3 labeled arugula seed powder portions. Patients add 1 arugula seed powder portion to each of 3 tomato-soy beverages immediately prior to consumption and they consume 1 beverage without the powder. After each beverage tasting, patients complete a survey on the sensory acceptability of the sample.
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||27 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||Acceptability in the Taste of Tomato-Soy-Arugula Seed Beverages in Men With Prostate Cancer|
|Study Start Date :||April 2015|
|Estimated Primary Completion Date :||April 2019|
Experimental: Prevention (dietary intervention, survey)
Patients receive 4 tomato-soy beverages and 3 labeled arugula seed powder portions. Patients add 1 arugula seed powder portion to each of 3 tomato-soy beverages immediately prior to consumption, and they consume 1 beverage without the powder. After each beverage tasting, patients complete a survey on the sensory acceptability of the sample.
Other: Survey Administration
Dietary Supplement: Tomato-Soy Juice
Receive tomato-soy beverages with or without varying levels of arugula seed powder
- Sensory acceptability of tomato-soy-arugula seed beverages assessed by survey [ Time Frame: Up to 2 years ]Mean plus/minus standard deviation will be used to express the results from the acceptability tests and the Just About Right tests. Ranking results will be analyzed by using t-test to obtain determine statistical significance. Significance level of the value will be chosen before statistic tests are conducted, at a value of 5%. A critical value below p < 0.05, will be considered statistically significant.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02927899
|United States, Ohio|
|Ohio State University Comprehensive Cancer Center|
|Columbus, Ohio, United States, 43210|
|Principal Investigator:||Steven Clinton, MD||Ohio State University Comprehensive Cancer Center|